IBIO Stock — iBio Inc.: Cash, EV, Pipeline

Share price

$1.28

Market cap

$82.3M

Cash

$88.0M

Enterprise value

-$5.7M

Balance sheet

Cash	$88.0M
Debt	$0.0M
Net cash	$88.0M
Enterprise value	-$5.7M
Basic shares	55.7M shares
Fully diluted shares	160.1M shares
Fully diluted market cap	$205.0M
Cash per share	$1.58

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading IBIO daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jun 12 - Jul 24	IBIO-600	Phase 1	Overweight , Obesity	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

IBIO-600

Preclinical · Active Modality: antibody

Target myostatin

Indications

Obesity (Preclinical)

Catalysts

— second quarter 2026

Status note Next-generation antibody therapeutic for obesity; company anticipated Phase 1a entry in Australia in the second quarter of 2026. Target not explicitly stated in the excerpts.

IBIO-610

Preclinical · Active Modality: antibody

Target Activin E

Partnerships AstralBio, Inc.: exclusive worldwide license agreement related to Activin E (April 21, 2025); AstralBio licensed its Activin E rights to the Company

Indications

Obesity (Preclinical)

Status note Preclinical long-acting Activin E-inhibiting antibody for obesity.

IBIO-101

Stage not disclosed · Active Modality: antibody

Partnerships RubrYc assets acquired September 16, 2022 (asset purchase agreement)

Indications

Oncology (Stage not disclosed)

Status note Oncology program acquired from RubrYc. Initiating in Q2 FY2026, the Company actively marketed and identified potential partners for IBIO-101 and the other oncology programs; oncology is de-prioritized relative to obesity. No stage disclosed.

Per-asset detail extracted from the 10-Q filed 2026-05-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	IBIO-600
Lead indication	Overweight , Obesity
Lead phase	Phase 1
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07487376	Phase 1	Recruiting	Sponsor	IBIO	—	Overweight , Obesity	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for iBio, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Frazier Life Sciences	1,953,467	no change	0.07%	2026-08-14
Ikarian Capital	957,062	no change	0.27%	2026-08-14
ADAR1 Capital Management	375,531	-94,347	0.03%	2026-08-14
Logos Global Management	0	-1,300,000	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

IBIO — iBio Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders